1. Home
  2. GNL vs NTLA Comparison

GNL vs NTLA Comparison

Compare GNL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Net Lease Inc.

GNL

Global Net Lease Inc.

HOLD

Current Price

$8.46

Market Cap

1.7B

Sector

Real Estate

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.19

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNL
NTLA
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
986.9M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GNL
NTLA
Price
$8.46
$9.19
Analyst Decision
Buy
Buy
Analyst Count
2
22
Target Price
$9.00
$19.83
AVG Volume (30 Days)
1.3M
4.1M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
8.99%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$751,333,000.00
$57,528,000.00
Revenue This Year
N/A
$1.96
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.63
33.52
52 Week Low
$6.51
$5.90
52 Week High
$8.49
$28.25

Technical Indicators

Market Signals
Indicator
GNL
NTLA
Relative Strength Index (RSI) 67.55 41.47
Support Level $8.20 $8.90
Resistance Level $8.40 $9.68
Average True Range (ATR) 0.13 0.52
MACD 0.02 0.37
Stochastic Oscillator 96.84 59.25

Price Performance

Historical Comparison
GNL
NTLA

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: